Orthopediatrics Corp. · NASDAQ:KIDS
Orthopediatrics — Investor Presentation (January 2020)
25 slides from Orthopediatrics's investor presentation, Jan 13, 2020
Slide 1: OrthoPediatrics Corp. January 2020
OrthoPediatrics Corp. Mark Throdahl, CEO January 2020 Fred Hite, CFO
Slide 2: Disclaimer
Disclaimer Forward-Looking Statements This presentation includes "forward-looking statements" within the meaning of U.S. federal securities laws. You can identify forward-looking statements by the use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "believ
Slide 3: Highlights
Highlights Large Market Proprietary Technology Scalable Business Diversified medical device company focused exclusively on pediatric orthopedics Protected market opportunity: $1.4 billion U.S., $3.2 billion globally (2019 estimates) High U.S. procedure concentration: <300 hospitals and ~1,400 surgeo
Slide 4: OP Today: A Company Built on a Cause
OP Today A Company Built on a CAUSE Cause Company Snapshot Improving the lives of children Treated 157,000 patients since inception with orthopedic conditions 33 surgical systems; ~7,500 SKUs; strong pipeline 3 additional systems from Vilex acquisition 88 direct employees; 158 focused sales reps1 Gl
Slide 5: Our Key Idea: Children Are Not Small Adults
Our Key Idea Children Are Not Small Adults Superior Clinical Outcomes OP’s Market Impact Re-Purposed Adult Plate OP’s Solution Address orthopedic industry’s lack of focus on product development, clinical education, and sales presence Implants and instruments avoid complications of re-purposed adult
Slide 6: Large and Focused Market
Large and Focused Market OP’S $3.2 Billion Current Addressable Global Market1 $1.4 Billion U.S. Addressable Market1 High Concentration of Pediatric Trauma & Deformity and Scoliosis Procedures 3,157 U.S. Sports Hospitals Medicine Smart $170M Implants $363M 38% Scoliosis Procedures $308M (%) 62% Traum
Slide 7: Product Line Diversification
Product Line Diversification 2018 Revenue by Segment $57.6 million sales in 2018, increasing 26% Scoliosis Well diversified sources of growth 29% All major product families supported FY 2018 26% revenue growth Sports Medicine/ Trauma & Firefly, PNP|Femur, and PediFrag were key 2% Deformity Other 69%
Slide 8: A Proven Strategy Since 2011
A Proven Strategy Since 2011 Sales Focus on Teaching Deploy Expand Expand Clinical Institutions and Instrument Addressable Education High Volume Sets Procedures Programs Hospitals Goals Accelerate sales growth Develop novel technologies 8
Slide 9: New Systems & Product Launches (2017-2018)
New Systems & Product Launches (2017-2018) Titanium Clavicle Wrist Fusion PediFlex Pediatric Nailing PediPlates® Plate System Plate System Advanced Platform | FEMUR System (First pediatric (First pediatric (Expands into adolescent (Expands physeal specific specific cases) Trauma Deformity & Trauma t
Slide 10: New Systems & Upcoming Product Launches (2019-2020)
New Systems & Upcoming Product Launches (2019-2020) Launched Launched Acquired Launched Launching Development Development Sept’19 Nov’19 June’19 Dec’19 1H’20 in Process in Process Trauma Deformity & Trauma Next Generation PediFoot Orthex QuickPack™ Slipped Capital Osteogenesis PNP | Tibia Cannulated
Slide 11: Strong Pipeline Expanding Our Addressable Market
Strong Pipeline Expanding Our Addressable Market CMF Clavicle Demonstrated ability to Proximal Rib expand portfolio to full Humerus Spine array of pediatric surgeries Elbow Growing Rods Hand & Wrist OP Today OP Tomorrow Now Under Development Pelvis Hip & Long Bone Knee (Sports Medicine) Foot & Ankle
Slide 12: Leading Edge Systems in Development
Leading Edge Systems in Development Smart Implants Early Onset Scoliosis Proof of concept established in 2018 with Emerging surgical trends not being pursued by substantial development in 2019 major spine companies Intervention in patients as young as 10 2 embodiments: (1) scoliosis (2) intramedulla
Slide 13: Global Sales Coverage
Global Sales Coverage United States International 75% of 2018 25% of 2018 Revenue Revenue 34 Sales Agencies, 7 Sales Agencies most of which are + 38 Stocking exclusive* Distributors* Direct in UK, IRE, AUS, NZ, CAN, BE, NL * Data as of 3Q 2019 Currently selling to major children’s hospitals in the U
Slide 14: Vilex Acquisition Transaction Details
Vilex Acquisition Transaction Details Acquisition: In June 2019 OP purchased Vilex1, including its Orthex Hexapod2 system and proprietary point-and-click planning software, for $60 million ($50 million cash + $10 million shares) Divestiture: In December 2019 OP sold the adult assets to Squadron Capi
Slide 15: Orthex Advantages
Orthex Advantages Disruptive Technology Construct allows 90° angulation Unique calibrated structs and HA-coated pins Patented point and click software Significantly simplifies surgery planning and subsequent alignments Dror Paley, MD – Pediatric orthopedic KOL Introduced Ilizarov method in U.S. Defe
Slide 16: Competitive Landscape
Competitive Landscape New Competitors Would Face Formidable Obstacles Product breadth Surgeon relationships Sales and distribution network Clinical education programs Pediatric brand equity Reputation with pediatric orthopedic societies Dynamic culture “The ship has sailed.” 16
Slide 17: What Does Category Leadership Mean?
What Does Category Leadership Mean? Surgeon relationships and Broadest, most innovative clinical education product offering Relationships with surgeons who use 13 years’ clinical understanding entire portfolio New product pipeline Major provider of clinical education Pediatric Market Gateway for Lea
Slide 18: Financial Review
Financial Review
Slide 19: Consistent 20+% Revenue Growth Since Inception
Consistent 20+% Revenue Growth Since Inception $75 $72.6 $70 $65 $60 $57.6 $55 $14.1 $50 $45.6 $45 $40 $37.3 $10.7 $35 $31.0 $8.5 $30 $6.1 $23.7 Revenue ($ in Millions) ($ Revenue $25 $19.6 $5.3 $43.5 $20 $16.1 $3.9 $34.9 $15 $2.8 $28.8 $10.2 $24.9 $10 $7.1 $0.9 $18.4 $13.3 $15.8 $5 $3.0 $0.4 $9.3 $
Slide 20: Category Revenue Summary
Category Revenue Summary $70 $1.3 $60 $1.2 $0.8 $50 $16.6 $1.2 $16.7 $1.1 $12.6 $40 $11.6 $1.1 $30 $9.4 $0.8 $7.4 $20 $3.6 $39.7 $35.7 Revenue Millions) in ($ Revenue $32.8 $29.5 $26.8 $22.5 $10 $19.3 $0 2014 2015 2016 2017 2018 9M 2018 9M 2019 Trauma & Deformity Scoliosis Sports Medicine/Other 20
Slide 21: Revenue Seasonality
Revenue Seasonality Seasonality Drives Stronger Performance in Summer Months and Holiday Periods 35% 29% 30% 27% 27% 27% 26% 26% 25% 26% 26% 25% 25% 26% 25% 22% 21% 21% 20% 20% 15% 10% Revenue as % of Total Year of % as Total Revenue 5% 0% 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 2016 2016 20
Slide 22: Income Statement Summary
Income Statement Summary ($ in Millions) FY 2016 FY 2017 FY 2018 9M 2018 9M 2019 Revenue $37.3 $45.6 $57.6 $43.0 $53.6 Growth % 20% 22% 26% 27% 25% Gross Profit $26.4 $34.5 $42.7 $32.2 $40.2 Margin % 71% 76% 74% 75% 75% Operating Expenses $32.5 $40.9 $52.2 $39.9 $46.2 Operating Loss ($6.1) ($6.5) ($
Slide 23: Adjusted EBITDA Reconciliation
Adjusted EBITDA Reconciliation ($ in Millions) Nine Months Ended September 30, 2018 2019 Net loss from continuing operations ($9.6) ($8.4) Interest expense, net 1.7 2.2 Other expense 0.1 0.1 Depreciation and amortization 2.2 3.2 Stock-based compensation 0.9 1.9 Accelerated vesting of restricted stoc
Slide 24: Balance Sheet
Balance Sheet ($ in Millions) As of September 30, 2019 Assets Liabilities Cash1 $19.7 Accounts payable $7.7 Accounts receivable 14.2 Debt2 51.2 Inventory (net) 34.5 Accrued expenses 3.9 Other current assets 40.3 All other liabilities 4.5 PP&E (net) 21.5 Paid-in capital 210.5 Intangibles 23.2 Accumul
Slide 25: Summary
Summary Surgeon relationships and Broadest, most innovative clinical education product offering Robust organic growth Attractive growth and opportunities margin profile 25
Orthopediatrics — Investor Presentation (January 2020) on 6ix